19 in stock
Semaglutide 10 mg is a long-acting GLP-1 receptor agonist with extensive human evidence across weight management, glucose control, cardiovascular outcomes, kidney health and metabolic liver research.
Semaglutide is a modified analogue of human glucagon-like peptide-1, or GLP-1. It is engineered to resist rapid enzymatic breakdown and remain active much longer than naturally produced GLP-1, allowing researchers to study sustained receptor activation.
Semaglutide is the active pharmaceutical ingredient used in regulated brand-name medicines such as Ozempic and Wegovy. Ozempic and Wegovy are distinct prescription products with their own approved formulations, delivery devices, indications and dosing schedules. A Canada Biogenix research vial is not either branded medicine and should not be described as equivalent to them.
The molecule activates GLP-1 receptors in the brain, pancreas and gastrointestinal system. This can influence satiety, food intake, glucose-dependent insulin secretion, glucagon release and gastric emptying. Its unusually broad clinical program has also revealed important cardiovascular, kidney and liver findings.
The landmark STEP 1 trial reported an average 14.9% weight reduction at 68 weeks, with approximately half of participants losing at least 15%.
The 17,604-participant SELECT trial reported a 20% relative reduction in major cardiovascular events among adults with overweight or obesity and established cardiovascular disease.
Dedicated trials have produced positive findings involving A1C, chronic kidney disease, cardiovascular risk and metabolic liver disease.
| Research action | Biological effect | Potential outcome |
|---|---|---|
| Central GLP-1 signalling | Supports satiety and reduces reward-driven or excessive food intake | Lower energy intake and sustained weight reduction |
| Glucose-dependent insulin release | Enhances insulin response when glucose is elevated | Improved post-meal and longer-term glycemic control |
| Reduced glucagon signalling | Limits inappropriate hepatic glucose release | Lower fasting and between-meal glucose exposure |
| Slower gastric emptying | Changes the rate at which nutrients enter the intestine | Greater fullness and a moderated post-meal glucose rise |
| Study | Population | Encouraging result | Research significance |
|---|---|---|---|
| STEP 1 | 1,961 adults with obesity or overweight without diabetes | Average weight reduction of 14.9% at 68 weeks versus 2.4% with placebo; about half lost at least 15%. | Established single-receptor GLP-1 agonism as a major weight-management pathway. |
| SELECT | 17,604 adults with overweight or obesity and established cardiovascular disease, without diabetes | Major cardiovascular events occurred in 6.5% with semaglutide versus 8.0% with placebo—a 20% relative risk reduction. | Demonstrated cardiovascular benefit in a large population without diabetes. |
| FLOW | 3,533 adults with type 2 diabetes and chronic kidney disease | The primary kidney and cardiovascular composite was 24% lower; major cardiovascular events were 18% lower and all-cause death was 20% lower. | Extended GLP-1 research into dedicated kidney-outcome protection. |
| ESSENCE | Adults with MASH and moderate or advanced liver fibrosis | MASH resolution without worsening fibrosis occurred in 62.9% versus 34.3% with placebo; fibrosis improvement occurred in 36.8% versus 22.4%. | Produced strong Phase 3 evidence across liver histology and metabolic disease. |
| SUSTAIN program | Adults with type 2 diabetes across multiple controlled trials | Consistent A1C reduction, weight improvement and cardiovascular-risk findings across different background therapies. | Created a mature clinical foundation for glucose and cardiometabolic research. |
Semaglutide supports glucose-dependent insulin secretion and has produced substantial, durable A1C improvements across the SUSTAIN clinical program.
Large outcomes trials reported fewer cardiovascular deaths, nonfatal heart attacks and nonfatal strokes in well-defined high-risk populations.
FLOW found slower kidney-function decline and fewer major kidney or cardiovascular events among adults with diabetes and chronic kidney disease.
ESSENCE demonstrated improvements in both MASH resolution and liver fibrosis, expanding interest beyond glucose and body weight.
Semaglutide remains one of the best-validated metabolic compounds, but its single GLP-1 mechanism appears less powerful for average weight reduction than the emerging triple-agonist approach. The STEP 1 trial reported 14.9% average weight reduction with standard high-dose semaglutide. By comparison, retatrutide reported 24.2% at 48 weeks in Phase 2 and approximately 28% in higher-dose Phase 3 groups.
This gap is biologically plausible. Semaglutide activates GLP-1 alone, whereas retatrutide combines GIP, GLP-1 and glucagon-receptor activity to influence appetite, glucose response, lipid mobilization and energy expenditure together.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Receptor activity | GLP-1 single agonist | GIP + GLP-1 + glucagon triple agonist |
| Representative average weight finding | 14.9% at 68 weeks in STEP 1 | 28.3% at 80 weeks in TRIUMPH-1 |
| Main strength | Mature clinical evidence across weight, cardiovascular, kidney and liver outcomes | Greater emerging weight-loss potential through three coordinated pathways |
| Development status | Extensively studied with multiple regulated pharmaceutical formulations | Investigational molecule with positive Phase 3 topline results |
Bottom line: semaglutide offers the more established evidence base, but it falls noticeably short of retatrutide’s reported average weight reductions. These figures come from separate trials rather than a randomized head-to-head comparison, so population and protocol differences still matter. Explore Retatrutide 10 mg and Retatrutide 20 mg for the triple-agonist research overview.
The Canadian patent barrier protecting semaglutide expired in early 2026. As a result, Canada became one of the first major markets where regulated generic competition could begin.
Health Canada approved the first generic semaglutide injection from Dr. Reddy’s Laboratories in April 2026. Additional approvals have followed, including Aspen-Semaglutide in July 2026, while other manufacturers have also pursued Canadian submissions. This new competition may expand access and place downward pressure on prices as supply becomes available.
Importantly, patent expiry does not make every semaglutide preparation a regulated generic. A pharmaceutical generic must receive Health Canada authorization and meet specific standards for identity, formulation, quality and comparability. Semaglutide 10 mg from Canada Biogenix remains a research product and is not represented as a generic version of Ozempic, Wegovy or another prescription medicine.
The 10 mg designation identifies the total research material contained in this vial. It is not a recommended dose, injection amount, cycle length or administration schedule.
Ozempic, Wegovy and approved generic semaglutide products use controlled pharmaceutical formulations, validated delivery systems and indication-specific schedules. Their labelled instructions belong only to those regulated products and should not be transferred to a research vial.
Canada Biogenix does not provide a human dosing, reconstitution or administration protocol for Semaglutide 10 mg. Experimental design should be determined by qualified researchers using validated laboratory methods and institutionally approved procedures.
Semaglutide’s clinical evidence is extensive and highly positive. Gastrointestinal effects—particularly nausea, diarrhea, vomiting and constipation—remain the most commonly reported tolerability issues and are usually most noticeable during dose escalation.
Researchers continue to study long-term weight maintenance, lean-mass preservation, gallbladder and pancreatic events, diabetic-retinopathy risk during rapid glucose improvement, and how individual response varies. Weight regain after treatment withdrawal also shows that sustained metabolic intervention may be necessary for durable outcomes.
Overall, semaglutide established GLP-1 receptor agonism as a major metabolic research platform. Its greatest strengths are evidence maturity and benefits across several organ systems; its principal limitation is that newer dual- and triple-agonist compounds may produce greater average weight change.
| Research product | Primary pathway | Main distinction |
|---|---|---|
| Semaglutide 10 mg | GLP-1 | Highly established single-incretin evidence |
| Tirzepatide 10 mg | GIP + GLP-1 | Dual-incretin signalling with greater average weight reduction in direct comparison |
| Retatrutide 10 mg | GIP + GLP-1 + glucagon | Triple-agonist approach with substantially higher emerging weight findings |
| MOTS-C 10 mg | Mitochondrial and AMPK signalling | Cellular-energy and metabolic-flexibility research |
Semaglutide 10 mg is supplied for qualified laboratory research and analytical applications. It is not represented as Ozempic, Wegovy, an approved generic or another regulated therapeutic product, and this page does not provide medical advice or a human administration protocol.
